Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Special Issue: Current evidence and perspectives for hypertension management in Asia
  • Published:

Patient preference for renal denervation therapy in hypertension: A cross-sectional survey in Chengdu, China

Hypertension Research volume 45, pages 954–961 (2022)Cite this article

A Comment to this article was published on 09 June 2022

Abstract

This study investigated patient preferences for renal denervation (RDN) therapy in hypertension patients in Chengdu, China. A questionnaire-based cross-sectional study was conducted between August and December 2020. First, we collected and analyzed information on demographics, the duration of hypertension, the presence or absence of medication, the medication regimen, the duration of medication, maximal and minimal blood pressure levels, self-reported comorbidities, the willingness of patients to choose RDN as a blood pressure control strategy, choice determinants and expectations for RDN. In total, 485 patients were interviewed, and 402 questionnaires were eligible for analysis. The mean age of the participants was 61 years, 53.9% of the participants were male, and 32.6% of the patients demonstrated a willingness to choose RDN as a blood pressure control strategy. The proportion of patients who were already on medication was 34.7%, whereas the proportion of those who were not on medication was 23.3%. Furthermore, 47.3% of the patients would choose RDN treatment if the procedure could decrease their blood pressure by over 20 mmHg, while no patient would choose the device treatment if their blood pressure would decrease by less than 5 mmHg. In addition, 56.5% of the patients expected that they could take one less medication after RDN. Approximately 70% of the patients expected that RDN could consistently decrease their blood pressure for at least 15 years. In summary, among hypertensive patients in Chengdu, an estimated one-third were willing to choose RDN therapy as a blood pressure control approach; these patients were younger, more likely to be male, took more antihypertensive drugs, and had concomitant metabolic disorders. The perspectives of patients on RDN were not dependent on their education levels; also, their expectations for RDN were high.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. GBD 2016 Risk Factors Collaborators. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390:1345–422. https://doi.org/10.1016/S0140-6736(17)32366-8.

    Article  Google Scholar 

  2. Kandzari DE, Böhm M, Mahfoud F, Townsend RR, Weber MA, Pocock S. et al. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet. 2018;391:2346–55. https://doi.org/10.1016/S0140-6736(18)30951-6.

    Article  PubMed  Google Scholar 

  3. Böhm M, Kario K, Kandzari DE, Mahfoud F, Weber MA, Schmieder RE. et al. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. Lancet. 2020;395:1444–51. https://doi.org/10.1016/S0140-6736(20)30554-7.

    Article  PubMed  Google Scholar 

  4. Fengler K, Rommel KP, Blazek S, Besler C, Hartung P, von Roeder M. et al. A three-arm randomized trial of different renal denervation devices and techniques in patients with resistant hypertension (RADIOSOUND-HTN). Circulation. 2019;139:590–600. https://doi.org/10.1161/CIRCULATIONAHA.118.037654.

    Article  PubMed  Google Scholar 

  5. Schmieder RE, Högerl K, Jung S, Bramlage P, Veelken R, Ott C. Patient preference for therapies in hypertension: a cross-sectional survey of German patients. Clinical research in cardiology: official journal of the German Cardiac. Society. 2019;108:1331–42. https://doi.org/10.1007/s00392-019-01468-0.

    Article  Google Scholar 

  6. Schmieder RE, Kandzari DE, Wang TD, Lee YH, Lazarus G, Pathak A. Differences in patient and physician perspectives on pharmaceutical therapy and renal denervation for the management of hypertension. J Hypertens. 2021;39:162–8. https://doi.org/10.1097/HJH.0000000000002592.

    Article  CAS  PubMed  Google Scholar 

  7. Schmieder RE, Mahfoud F, Mancia G, Azizi M, Böhm M, Dimitriadis K. et al. European Society of Hypertension position paper on renal denervation 2021. J Hypertens. 2021;39:1733–41. https://doi.org/10.1097/HJH.0000000000002933.

    Article  CAS  PubMed  Google Scholar 

  8. Kario K, Kagitani H, Hayashi S, Hanamura S, Ozawa K, Kanegae H. A Japan nationwide web-based survey of patient preference for renal denervation for hypertension treatment. Hypertension Res: Off J Jpn Soc Hypertension. 2022;45:232–40. https://doi.org/10.1038/s41440-021-00760-9.

    Article  Google Scholar 

  9. Mahfoud F, Schlaich M, Kindermann I, Ukena C, Cremers B, Brandt MC. et al. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation. 2011;123:1940–6. https://doi.org/10.1161/CIRCULATIONAHA.110.991869.

    Article  CAS  PubMed  Google Scholar 

  10. Pourmoghaddas M, Khosravi A, Akhbari M, Akbari M, Pourbehi M, Ziaei F, et al. One year follow-up effect of renal sympathetic denervation in patients with resistant hypertension. ARYA Atheroscler. 2016;12:109–13.

    PubMed  PubMed Central  Google Scholar 

  11. Witkowski A, Prejbisz A, Florczak E, Kądziela J, Śliwiński P, Bieleń P. et al. Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension. 2011;58:559–65. https://doi.org/10.1161/HYPERTENSIONAHA.111.173799.

    Article  CAS  PubMed  Google Scholar 

  12. Beaney T, Schutte AE, Stergiou GS, Borghi C, Burger D, Charchar F. et al. May measurement month 2019: the global blood pressure screening campaign of the international society of hypertension. Hypertension. 2020;76:333–41. https://doi.org/10.1161/HYPERTENSIONAHA.120.14874.

    Article  CAS  PubMed  Google Scholar 

  13. Burnier M, Egan BM. Adherence in hypertension. Circulation Res. 2019;124:1124–40. https://doi.org/10.1161/CIRCRESAHA.118.313220.

    Article  CAS  PubMed  Google Scholar 

  14. Vrijens B, Vincze G, Kristanto P, Urquhart J, Burnier M. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ. 2008;336:1114–7. https://doi.org/10.1136/bmj.39553.670231.25.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Mahfoud F, Böhm M, Schmieder R, Narkiewicz K, Ewen S, Ruilope L. et al. Effects of renal denervation on kidney function and long-term outcomes: 3-year follow-up from the Global SYMPLICITY Registry. Eur Heart J. 2019;40:3474–82. https://doi.org/10.1093/eurheartj/ehz118.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Kario, K, Yokoi, Y, Okamura, K, Fujihara, M, Ogoyama, Y, Yamamoto, E, et al. (2021). Catheter-based ultrasound renal denervation in patients with resistant hypertension: the randomized, controlled REQUIRE trial. Hypertension Research. 2021. https://doi.org/10.1038/s41440-021-00754-7. Accessed 15 Oct 2021.

  17. Glybochko PV, Svetankova AA, Rodionov AV, Maltseva AS, Sulimov VA, Fomin VV. Renal denervation with a resistant arterial hypertension: the results of a five-year follow-up. Terapevticheskii Arkhiv. 2018;90:88–91. https://doi.org/10.26442/terarkh201890988-91.

    Article  CAS  PubMed  Google Scholar 

  18. Dong, Zhao. (2021). Epidemiological features of cardiovascular disease in Asia. JACC: Asia. 2021;1:1–13. https://doi.org/10.1016/j.jacasi.2021.04.007.

  19. Arima H, Murakami Y, Lam TH, Kim HC, Ueshima H, Woo J. et al. Effects of prehypertension and hypertension subtype on cardiovascular disease in the Asia-Pacific Region. Hypertension. 2012;59:1118–23. https://doi.org/10.1161/HYPERTENSIONAHA.111.187252.

    Article  CAS  PubMed  Google Scholar 

  20. Kario K, Kim BK, Aoki J, Wong AY, Lee YH, Wongpraparut N. et al. Renal denervation in asia: consensus statement of the asia renal denervation consortium. Hypertension. 2020;75:590–602. https://doi.org/10.1161/HYPERTENSIONAHA.119.13671.

    Article  CAS  PubMed  Google Scholar 

  21. Kim BK, Böhm M, Mahfoud F, Mancia G, Park S, Hong MK. et al. Renal denervation for treatment of uncontrolled hypertension in an Asian population: results from the Global SYMPLICITY Registry in South Korea (GSR Korea). J Hum Hypertension. 2016;30:315–21. https://doi.org/10.1038/jhh.2015.77.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We acknowledge Professor Xiongjing Jiang and Professor Xiaoping Chen for their promotion of the RDN technique and related research in West China Hospital.

Author information

Author notes

  1. These authors contributed equally: Zhipeng Zhang, Xin Zhang

Authors and Affiliations

  1. Department of Cardiology, West China Hospital, Sichuan University, Chengdu, China

    Zhipeng Zhang, Xin Zhang, Runyu Ye, Xinran Li & Xiaoping Chen

Authors
  1. Zhipeng Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xin Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Runyu Ye
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xinran Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Xiaoping Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Xiaoping Chen.

Ethics declarations

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhang, Z., Zhang, X., Ye, R. et al. Patient preference for renal denervation therapy in hypertension: A cross-sectional survey in Chengdu, China. Hypertens Res 45, 954–961 (2022). https://doi.org/10.1038/s41440-022-00912-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41440-022-00912-5

Keywords

This article is cited by

Search

Advanced search

Quick links